1020：ACE-Breast-02：一种新型抗HER2 ADC药物ARX788，联合拉帕替尼及卡培他滨治疗HER2阳性晚期乳腺癌的关键II/III期试验

ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC)

1009：DESTINY-Breast07：德曲妥珠单抗（T-DXd）单药或联合帕妥珠单抗在既往未接受过治疗的HER2阳性转移性乳腺癌的剂量扩展中期分析

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

550：新辅助化疗后存在残留病变的HER2阳性乳腺癌患者使用HER2多肽疫苗联合T-DM1治疗的安全性导入结果

Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.

1023：来自DESTINY-Breast-01, -02, and -03研究的HER2阳性转移性乳腺癌患者对T-DXd的最佳完全缓解率的汇总分析

Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.

1024：T-DXd在英国治疗转移性乳腺癌的真实世界经验

Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.

1025：T-DXd与T-DM1在HER2阳性转移性乳腺癌患者的比较：DESTINY-Breast03的最新生存结果

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.

1031：比较T-DM1与曲妥珠单抗联合帕妥珠单抗及多西他赛治疗老年HER2阳性晚期乳腺癌患者的III期研究（JCOG1607 HERB TEA）中根据年龄和老年综合评估进行的亚组分析

The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study).

1032：T-DXd治疗乳腺癌伴脑转移：DE-REAL研究

Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.

1034：T-DXd在HER2阳性和HER2低表达转移性乳腺癌患者的安全性和疗效：一项最新的临床试验系统综述和荟萃分析

Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials.

1036：HER2低表达和HER2阳性转移性乳腺癌伴或不伴脑转移的患者接受T-DXd治疗的生存分析比较

Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan.

1077：在转移性乳腺癌患者的大型真实世界数据库中按HER2状态和治疗线分析T-DXd的治疗结局

Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.

1083：在HER2低表达转移性乳腺癌患者中序贯使用T-DXd和戈沙妥珠单抗（SG）的多中心回顾性队列研究：更新结果，以及按年龄、疾病部位和干预治疗的使用情况进行的亚组分析

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.

1085：转移性乳腺癌接受ADC药物（SG和T-DXd）序贯治疗的真实世界结局

Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.

1110：101研究中BB-1701在HER2低表达局部晚期/转移性乳腺癌患者多剂量水平队列中的最新安全性和抗肿瘤活性

Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.

1112：转移性乳腺癌患者使用T-DXd治疗的经济毒性

Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd).

1504：接受T-DXd治疗的转移性乳腺癌患者中比较电子化患者报告结局（ePRO）与常规随访的随机研究（PRO-DUCE研究）

A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).

11145：转移性乳腺癌患者接受T-DXd治疗的肺毒性：梅奥诊所经验

Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience.

TPS1120：EZH1/2抑制剂valemetostat联合T-DXd治疗HER2低表达/超低表达/零表达的转移性乳腺癌的1b期研究

Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.

TPS1121：新型HER2靶向免疫刺激抗体偶联物（ISAC）TLR7/8激动剂BDC-1001+/-帕妥珠单抗用于既往接受过T-DXd治疗的HER2阳性转移性乳腺癌患者的II期研究

Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).

TPS1122：一项开放标签、多中心、II期研究，旨在评估HER2靶向ADC药物BB-1701用于既往接受过治疗的HER2阳性或HER2低表达不可切除/转移性乳腺癌患者的安全性和有效性

An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).

TPS1123：ACE-BREAST-03：评估ARX788用于既往接受过T-DXd治疗的HER2阳性转移性乳腺癌患者的II期临床研究

ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).

TPS631：HER2阳性早期乳腺癌中，基于新辅助动态标志物调整个性化治疗，比较T-DXd与紫杉醇/多西他赛联合卡培他滨和曲帕双靶的研究：WSG-ADAPT-HER2-IV

Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.

e12518：在HER2阳性和HER2低表达晚期肿瘤患者中评估T-DXd的真实世界安全性和停药率

Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer.

e12636：HER2 ADC药物RC48在HER2阳性乳腺癌新辅助治疗的疗效和安全性：一项单臂II期研究

Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study.

e13001：T-DM1在沙特HER2阳性转移性乳腺癌患者的疗效和毒性

Efficacy and toxicity of trastuzumab emtansine among patients with HER-2-positive metastatic breast cancer in Saudi Arabia.

e13005：吡咯替尼联合T-DM1用于HER2阳性晚期乳腺癌患者的疗效和安全性：一项单臂、II期试验

Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.

e13011：RC48用于HER2表达乳腺癌的疗效和安全性：一项多中心、回顾性研究

Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study.

e13020：新型HER2靶向ADC药物GQ1001联合吡咯替尼用于既往接受过治疗的HER2阳性转移性乳腺癌患者的安全性和初步疗效：Ib期临床研究

Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.

e13022：RC48用于既往接受过治疗的HER2阳性晚期乳腺癌的有效性和安全性：中国真实世界经验

Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.

e13025：接受T-DXd或T-DM1二线治疗的HER2阳性转移性乳腺癌患者至下次治疗时间的真实世界数据比较

Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine.

e13026：T-DM1在中国HER2阳性转移性乳腺癌患者的应用：一项多中心、回顾性、真实世界研究

T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study.

e13117：T-DXd治疗转移性乳腺癌的中枢神经系统（CNS）疗效：一项单中心、真实世界分析

CNS efficacy of trastuzumab deruxtecan in metastatic breast cancer: A single-institution, real-world analysis.

e13159：ARX788联合特瑞普利单抗用于HER2低表达晚期乳腺癌和其他HER2表达实体瘤的Ia/b期试验

A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors.

e13164：基于HER2免疫组化（IHC）的T-DXd治疗HER2低表达转移性乳腺癌疗效差异的荟萃分析

A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC).

e13169：HER2低表达转移性患者在转移性阶段接受化疗后序贯化疗或T-DXd的至下一次治疗时间的真实世界数据比较

Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting.

e14012：T-DXd治疗转移性乳腺癌患者的CNS疗效的荟萃分析

A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC).

LBA509：Dato-DXd新辅助治疗的病理学完全缓解（pCR）率：来自I-SPY2.2研究的结果

Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.

LBA501：Dato-DXd联合度伐利尤单抗新辅助治疗的pCR率：来自I-SPY2.2研究的结果

Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.

LBA1004：SACI-IO HR+：在HR阳性/HER2阴性转移性乳腺癌患者评估SG联合或不联合帕博利珠单抗的随机II期试验

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

1006：Dato-DXd和化疗用于既往接受过治疗的HR阳性/HER2阴性不可手术或转移性乳腺癌患者的比较：来自TROPION-Breast01研究的PRO

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.

104：OptiTROP-Breast01研究结果：Sacituzumab tirumotecan（SKB264/MK-2870）用于既往接受过治疗过的局部复发或转移性三阴性乳腺癌（TNBC）患者

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

1075：HR阳性/HER2阴性转移性乳腺癌中DNA损伤反应（DDR）基因组改变及其对SG临床疗效的影响：TROPICS-02研究的生物标志物结果

Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.

1091：Trilaciclib联合SG治疗转移性TNBC：最新的II期安全性和有效性结果

Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.

1101：TNBC或HR阳性/HER2阴性晚期乳腺癌患者中SG治疗相关的中性粒细胞减少和腹泻的预防：II期临床试验

Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

1102：SG和talazoparib序贯联合治疗转移性TNBC：一项II期研究的结果

Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.

TPS1140：立体定向放疗联合SG和赛帕利单抗治疗TNBC伴脑转移的I/II期研究

Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases.

e13085：SG治疗HR阳性/HER2阴性晚期乳腺癌的疗效和安全性：一项综合系统综述和荟萃分析

Efficacy and safety of sacituzumab govitecan in HR+/HER2– advanced breast cancer: A comprehensive systematic review and meta-analysis.

e13106：SG在乳腺癌患者的安全性：一项系统综述和荟萃分析

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.

e13131：TROP2 ADC药物F0024用于晚期实体瘤患者的剂量递增和扩展的I期研究结果

Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.

e13132：TROP2 ADC药物ESG401一线治疗转移性mTNBC

ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).

e13137：SG治疗乳腺癌的真实世界结局

Real-world outcomes of sacituzumab govitecan in breast cancer.

1005：EV-202研究中Enfortumab vedotin在TNBC和HR阳性/HER2阴性乳腺癌队列的应用

Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.

TPS2091：HER3-DXd—Patritumab deruxtecan用于转移性乳腺癌和非小细胞肺癌伴活动性脑转移，以及晚期实体瘤软脑膜病变：II期TUXEDO-3研究

e13174：ADC药物在HER2低表达晚期/转移性乳腺癌患者的应用：一项系统综述和荟萃分析

Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis.